Search

Your search keyword '"Toze, Cynthia L."' showing total 204 results
Start Over Author "Toze, Cynthia L." Publication Type Academic Journals
204 results on '"Toze, Cynthia L."'

1. Outcomes with allogeneic stem cell transplant using cryopreserved versus fresh hematopoietic progenitor cell products

Author

Wan, Bo (Angela), Lindo, Lorenzo, Mourad, Yasser Abou, Chung, Shanee, Forrest, Donna, Kuchenbauer, Florian, Nantel, Stephen, Narayanan, Sujaatha, Nevill, Tomas, Power, Maryse, Rodrigo, Judith, Sanford, David, Song, Kevin, Stubbins, Ryan J., Sutherland, Heather, Toze, Cynthia L., White, Jennifer, Roy, Claudie, and Hay, Kevin A.

Published
2024
Full Text
View/download PDF

4. Ultrasensitive Detection of NOTCH1 c.7544_7545delCT Mutations in Chronic Lymphocytic Leukemia by Droplet Digital PCR Reveals High Frequency of Subclonal Mutations and Predicts Clinical Outcome in Cases with Trisomy 12

Author

Hoofd, Catherine, Huang, Steven J., Gusscott, Samuel, Lam, Sonya, Wong, Rachel, Johnston, Alexa, Ben-Neriah, Susana, Steidl, Christian, Scott, David W., Bruyere, Helene, Gillan, Tanya L., Toze, Cynthia L., Gerrie, Alina S., and Weng, Andrew P.

Published
2020
Full Text
View/download PDF

7. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis

Author

Limvorapitak, Wasithep, Barnett, Michael J., Hogge, Donna E., Forrest, Donna L., Nevill, Thomas J., Narayanan, Sujaatha, Power, Maryse M., Nantel, Stephen H., Broady, Raewyn, Song, Kevin W., Toze, Cynthia L., Mourad, Yasser Abou, Sutherland, Heather J., Gerrie, Alina S., White, Jennifer, and Sanford, David S.

Published
2018
Full Text
View/download PDF

10. The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants

Author

Rio-Machin, Ana, Vulliamy, Tom, Hug, Nele, Walne, Amanda, Tawana, Kiran, Cardoso, Shirleny, Ellison, Alicia, Pontikos, Nikolas, Wang, Jun, Tummala, Hemanth, Al Seraihi, Ahad Fahad H., Alnajar, Jenna, Bewicke-Copley, Findlay, Armes, Hannah, Barnett, Michael, Bloor, Adrian, Bödör, Csaba, Bowen, David, Fenaux, Pierre, Green, Andrew, Hallahan, Andrew, Hjorth-Hansen, Henrik, Hossain, Upal, Killick, Sally, Lawson, Sarah, Layton, Mark, Male, Alison M., Marsh, Judith, Mehta, Priyanka, Mous, Rogier, Nomdedéu, Josep F., Owen, Carolyn, Pavlu, Jiri, Payne, Elspeth M., Protheroe, Rachel E., Preudhomme, Claude, Pujol-Moix, Nuria, Renneville, Aline, Russell, Nigel, Saggar, Anand, Sciuccati, Gabriela, Taussig, David, Toze, Cynthia L., Uyttebroeck, Anne, Vandenberghe, Peter, Schlegelberger, Brigitte, Ripperger, Tim, Steinemann, Doris, Wu, John, Mason, Joanne, Page, Paula, Akiki, Susanna, Reay, Kim, Cavenagh, Jamie D., Plagnol, Vincent, Caceres, Javier F., Fitzgibbon, Jude, and Dokal, Inderjeet

Published
2020
Full Text
View/download PDF

12. Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells

Author

Kariminia, Amina, Holtan, Shernan G., Ivison, Sabine, Rozmus, Jacob, Hebert, Marie-Josée, Martin, Paul J., Lee, Stephanie J., Wolff, Daniel, Subrt, Peter, Abdossamadi, Sayeh, Sung, Susanna, Storek, Jan, Levings, Megan, Aljurf, Mahmoud, Arora, Mukta, Cutler, Corey, Gallagher, Geneviève, Kuruvilla, John, Lipton, Jeff, Nevill, Thomas J., Newell, Laura F., Panzarella, Tony, Pidala, Joseph, Popradi, Gizelle, Szwajcer, David, Tay, Jason, Toze, Cynthia L., Walker, Irwin, Couban, Stephen, Storer, Barry E., and Schultz, Kirk R.

Published
2016
Full Text
View/download PDF

13. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors

Author

Nair, Anish P., Barnett, Michael J., Broady, Raewyn C., Hogge, Donna E., Song, Kevin W., Toze, Cynthia L., Nantel, Stephen H., Power, Maryse M., Sutherland, Heather J., Nevill, Thomas J., Abou Mourad, Yasser, Narayanan, Sujaatha, Gerrie, Alina S., and Forrest, Donna L.

Published
2015
Full Text
View/download PDF

14. Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Nonfollicular Indolent Lymphoma

Author

Villa, Diego, George, Anupkumar, Seymour, John F., Toze, Cynthia L., Crump, Michael, Lee, Christina, Buckstein, Rena, Stewart, Douglas A., MacDonald, David, Foley, Ronan, Xenocostas, Anargyros, Sabloff, Mitchell, Chua, Neil, Couture, Felix, Larouche, Jean F., Cohen, Sandra, Savage, Kerry J., Connors, Joseph M., Panzarella, Tony, Carney, Dennis A., Dickinson, Michael, and Kuruvilla, John

Published
2014
Full Text
View/download PDF

16. Autologous Stem Cell Transplantation for Treatment with Curative Intent in Adult Patients with Acute Lymphoblastic Lymphoma

Author

Bazin, Jessica L., Abou Mourad, Yasser, Forrest, Donna L., Hay, Kevin, Kuchenbauer, Florian, Nantel, Stephen H., Narayanan, Sujaatha, Nevill, Thomas J., Power, Maryse, Rodrigo, Judith A, Roy, Claudie, Sanford, David, Song, Kevin, Stubbins, Ryan J., Sutherland, Heather J., Toze, Cynthia L., White, Jennifer, and Chung, Shanee

Published
2022
Full Text
View/download PDF

17. Clinical Outcomes in Fresh Versus Cryopreserved Hematopoietic Stem Cell Products in British Columbia: A Retrospective Study

Author

Wan, Bo, Lindo, Lorenzo, Cameron, Giovanna, Abou Mourad, Yasser, Chung, Shanee, Forrest, Donna L., Kuchenbauer, Florian, Nantel, Stephen H., Narayanan, Sujaatha, Nevill, Thomas J., Power, Maryse, Rodrigo, Judith A, Sanford, David, Song, Kevin, Stubbins, Ryan J, Sutherland, Heather J., Toze, Cynthia L., White, Jennifer K., Roy, Claudie, and Hay, Kevin A.

Published
2022
Full Text
View/download PDF

19. Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada.

Author

Khelifi, Rania S., Huang, Steven J., Savage, Kerry J., Villa, Diego, Scott, David W., Ramadan, Khaled, Connors, Joseph M., Sehn, Laurie H., Toze, Cynthia L., and Gerrie, Alina S.

Subjects
CHRONIC lymphocytic leukemia, SURVIVAL rate, OVERALL survival
Abstract

Ibrutinib has dramatically changed the treatment landscape for chronic lymphocytic leukemia (CLL) since its availability in British Columbia (BC), Canada in 2014. We analyzed patterns of use and real-world survival outcomes in 370 patients who received ibrutinib for first-line (1 L, n = 35) and relapsed/refractory (R/R, n = 335) CLL between 2014–2018 in BC. Dose reductions and interruptions were frequent in 32% and 27%, respectively. With a median follow-up of 27.6 months, 35% of patients discontinued ibrutinib, primarily for adverse events (AEs) rather than progressive disease. Over the course of treatment, 87% of patients experienced at least one adverse event. The 2-year overall survival (OS) and event-free survival (EFS) were excellent at 83.9% and 76.1%, respectively, with medians not reached. However, patients who discontinued ibrutinib had a median OS of 32.5 months and median EFS of only 3.8 months from time of discontinuation, highlighting the need to minimize toxicity in the real-world. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

20. Response to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myelogenous Leukemia Relapsing in Chronic and Advanced Phase Following Allogeneic Hematopoietic Stem Cell Transplantation

Author

Wright, Matthew P., Shepherd, John D., Barnett, Michael J., Nantel, Stephen H., Sutherland, Heather J., Toze, Cynthia L., Hogge, Donna E., Nevill, Thomas J., Song, Kevin W., Abou Mourad, Yasser R., Narayanan, Sujaatha, Power, Maryse M., Smith, Clayton A., and Forrest, Donna L.

Published
2010
Full Text
View/download PDF

22. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels

Author

Forrest, Donna L., Trainor, Shannon, Brinkman, Ryan R., Barnett, Michael J., Hogge, Donna E., Nevill, Thomas J., Shepherd, John D., Nantel, Stephen H., Toze, Cynthia L., Sutherland, Heather J., Song, Kevin W., Lavoie, Julye C., Power, Maryse M., Abou-Mourad, Yasser, and Smith, Clayton A.

Published
2009
Full Text
View/download PDF

25. Real-World Outcomes of Pfts in Screening for Lung Involvement in Chronic Gvhd Post-Allogeneic Stem Cell Transplant: A Retrospective Study of 387 Patients in British Columbia, Canada

Author

Wan, Bo, Mourad, Yasser Abou, Chung, Shanee, Forrest, Donna L., Kuchenbauer, Florian, Nantel, Stephen H., Narayanan, Sujaatha, Nevill, Thomas J., Power, Maryse, Rodrigo, Judith Anula, Sanford, David, Song, Kevin, Stubbins, Ryan J, Sutherland, Heather J., Toze, Cynthia L., White, Jennifer, Roy, Claudie, and Hay, Kevin A

Published
2023
Full Text
View/download PDF

28. Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia.

Author

Zhu, Kai, Jamroz, Andrew, Huang, Steven, Villa, Diego, Freeman, Ciara L., Scott, David W., Slack, Graham, Sehn, Laurie H., Connors, Joseph M., Toze, Cynthia L., Savage, Kerry J., and Gerrie, Alina S.

Subjects
RICHTER syndrome, LYMPHOCYTIC leukemia, LYMPHOMAS, PROGNOSIS, OLDER patients, CHRONIC leukemia
Abstract

Summary: Hodgkin variant Richter transformation (HvRT) is a rare and challenging complication of chronic lymphocytic leukaemia (CLL) for which information on prognostic factors and treatment approaches remain limited. We analysed characteristics and survival outcomes of a population‐based cohort of 32 patients with HvRT identified in British Columbia over a 40‐year period. Median interval from CLL diagnosis to HvRT was 5.6 years (range, 0–33.6), with five cases diagnosed concurrently. Most patients (80%) had treatment for CLL prior to HvRT. Median age at HvRT was 71 years (range, 51–86) and the majority of patients had high‐risk disease, including stage 3–4 in 87% and International Prognostic Score (IPS) ≥ 4 in 65%. Two‐year progression‐free (PFS) and overall survival (OS) from HvRT were 47% (95% CI: 29%–64%) and 57% (95% CI: 38%–72%), respectively. OS from HvRT was significantly worse in those with anaemia (p = 0.02), elevated lactate dehydrogenase (p = 0.04), high IPS (p = 0.04), and worse performance status (p = 0.001). For those treated with curative‐intent ABVD/ABVD‐like therapy, 2‐year PFS and OS were 70% (95% CI: 45%–85%) and 74% (95% CI: 49%–89%), respectively. In this real‐world population‐based cohort, HvRT was associated with poor clinical outcomes overall; however, those able to tolerate curative‐intent therapy had similar survival to older patients with de novo HL. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

33. Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real‐world outcomes from a population‐based cohort.

Author

Stubbins, Ryan J., Stamenkovic, Maria, Roy, Claudie, Rodrigo, Judith, Chung, Shanee, Kuchenbauer, Florian C., Hay, Kevin A., White, Jennifer, Abou Mourad, Yasser, Power, Maryse M., Narayanan, Sujaatha, Forrest, Donna L., Toze, Cynthia L., Sutherland, Heather J., Nantel, Stephen H., Nevill, Thomas J., Karsan, Aly, Song, Kevin W., and Sanford, David S.

Subjects
ACUTE myeloid leukemia, OLDER people, SOCIOECONOMIC factors, INDUCTION chemotherapy
Abstract

Objectives: Acute myeloid leukaemia (AML) is a disease of older adults, who are vulnerable to socio‐economic factors. We determined AML incidence in older adults and the impact of socio‐economic factors on outcomes. Methods: We included 3024 AML patients (1996–2016) identified from a population‐based registry. Results: AML incidence in patients ≥60 years increased from 11.01 (2001–2005) to 12.76 (2011–2016) per 100 000 population. Among 879 patients ≥60 years in recent eras (2010–2016), rural residents (<100 000 population) were less likely to be assessed by a leukaemia specialist (39% rural, 47% urban, p =.032); no difference was seen for lower (43%, quintile 1–3) vs. higher (47%, quintile 4–5) incomes (p =.235). Similar numbers received induction chemotherapy between residence (16% rural, 18% urban, p =.578) and incomes (17% lower, 17% high, p = 1.0). Differences between incomes were seen for hypomethylating agent treatment (14% low, 20% high, p =.041); this was not seen for residence (13% rural, 18% urban, p =.092). Among non‐adverse karyotype patients ≥70 years, 2‐year overall survival was worse for rural (5% rural, 12% urban, p =.006) and lower income (6% low, 15% high, p =.017) patients. Conclusions: AML incidence in older adults is increasing, and outcomes are worse for older rural and low‐income residents; these patients face treatment barriers. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

35. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors

Author

Lin, Yulia, Bruyère, Hélène, Horsman, Douglas E., Pantzar, Tapio, Barnett, Michael J., Hogge, Donna E., Nevill, Thomas J., Nantel, Stephen H., Sutherland, Heather J., Toze, Cynthia L., Shepherd, John D., Lavoie, Julye C., Song, Kevin W., Smith, Clayton A., and Forrest, Donna L.

Published
2006
Full Text
View/download PDF

36. Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort

Author

Toze, Cynthia L., Dalal, Chinmay B., Nevill, Thomas J., Gillan, Tanya L., Abou Mourad, Yasser R., Barnett, Michael J., Broady, Raewyn C., Forrest, Donna L., Hogge, Donna E., Nantel, Stephen H., Power, Maryse M., Song, Kevin W., Sutherland, Heather J., Smith, Clayton A., Narayanan, Sujaatha, Young, Sean S., Connors, Joseph M., and Shepherd, John D.

Published
2012
Full Text
View/download PDF

37. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver

Author

Lavoie, Julye C., Connors, Joseph M., Phillips, Gordon L., Reece, Donna E., Barnett, Michael J., Forrest, Donna L., Gascoyne, Randy D., Hogge, Donna E., Nantel, Stephen H., Shepherd, John D., Smith, Clayton A., Song, Kevin W., Sutherland, Heather J., Toze, Cynthia L., Voss, Nicholas J.S., and Nevill, Thomas J.

Published
2005
Full Text
View/download PDF

40. High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkinʼs Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation

Author

Forrest, Donna L., Hogge, Donna E., Nevill, Thomas J., Nantel, Stephen H., Barnett, Michael J., Shepherd, John D., Sutherland, Heather J., Toze, Cynthia L., Smith, Clayton A., Lavoie, Julye C., Song, Kevin W., Voss, Nicholas J., Gascoyne, Randy D., and Connors, Joseph M.

Published
2005
Full Text
View/download PDF

50. Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial

Author

Roy, Jean, Panzarella, Tony, Couban, Stephen, Couture, Félix, Devins, Gerald M., Elemary, Mohamed, Foley, Stephen Ronan, Gallagher, Genevieve, Kuruvilla, John, Lee, Stephanie J., Moore, John, Nevill, Thomas J, Popradi, Gizelle, Schultz, Kirk R., Szwajcer, David, Toze, Cynthia L, and Walker, Irwin

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results